Edition:
United States

GlycoMimetics Inc (GLYC.O)

GLYC.O on Consolidated Issue listed on NASDAQ Global Market

11.15USD
18 Oct 2017
Change (% chg)

$-0.34 (-2.96%)
Prev Close
$11.49
Open
$11.57
Day's High
$11.71
Day's Low
$11.13
Volume
153,661
Avg. Vol
515,149
52-wk High
$16.94
52-wk Low
$3.82

Latest Key Developments (Source: Significant Developments)

GlycoMimetics says files for mixed shelf of upto $250 mln
Thursday, 28 Sep 2017 05:59pm EDT 

Sept 28 (Reuters) - GlycoMimetics Inc :GlycoMimetics Inc says files for mixed shelf of upto $250.0 million - SEC filing‍​.  Full Article

Glycomimetics presents updated data from ongoing phase 1/2 clinical trial of GMI-1271 at ASCO
Monday, 5 Jun 2017 07:00am EDT 

June 5 (Reuters) - Glycomimetics Inc :Glycomimetics presents updated data from ongoing phase 1/2 clinical trial of GMI-1271 in patients with acute myeloid leukemia at ASCO 2017 annual meeting.Glycomimetics Inc says GMI-1271 continues to be well tolerated in combination with induction chemotherapy.Glycomimetics -remission rates continue to be higher than historical controls & induction-related mortality continues to be lower than historical controls.Glycomimetics Inc - in study only one case of severe (grade 3/4) mucositis reported among 79 patients receiving high-intensity induction chemotherapy.Glycomimetics Inc - relapsed/refractory patients with more blasts expressing e-selectin ligand were more likely to achieve complete response in study.  Full Article

Glycomimetics announces pricing of public offering of common stock
Wednesday, 24 May 2017 08:00am EDT 

May 24 (Reuters) - Glycomimetics Inc :Glycomimetics announces pricing of public offering of common stock.Says public offering of 7.00 million common shares priced at $11.50per share.  Full Article

Glycomimetics Inc terminates sales agreement with Cowen and Company
Wednesday, 24 May 2017 07:25am EDT 

May 24 (Reuters) - Glycomimetics Inc :Glycomimetics Inc - co terminated its sales agreement, dated March 1, 2016, with Cowen and Company.  Full Article

Glycomimetics announces proposed public offering of common stock
Monday, 22 May 2017 04:01pm EDT 

May 22 (Reuters) - Glycomimetics Inc :Glycomimetics announces proposed public offering of common stock.Intends to offer and sell, subject to market conditions, 6 million shares of common stock in an underwritten public offering.To use net proceeds to complete its ongoing phase 1/2 clinical trial of GMI-1271 in patients with acute myeloid leukemia (AML).Also intends to use net proceeds to complete its ongoing phase 1 clinical trial of GMI-1271 in patients with multiple myeloma (MM).  Full Article

Glycomimetics reports supportive biomarker data from early-stage trial of GMI-1271
Thursday, 18 May 2017 06:30am EDT 

May 18 (Reuters) - GlycoMimetics Inc -:GlycoMimetics announces high overall response rates, low induction mortality, promising initial survival outcomes, and supportive biomarker data from phase 1/2 trial of GMI-1271 in AML.  Full Article

Glycomimetics reports qtrly net loss per share of $0.34
Monday, 8 May 2017 09:00am EDT 

May 8 (Reuters) - Glycomimetics Inc :Glycomimetics reports program updates and first quarter 2017 results.Qtrly net loss per share $0.34.Qtrly loss per share $0.34.Phase 3 program to evaluate Rivipansel for vaso-occlusive sickle cell crisis, according to Pfizer, remains on track for completion in H2 2018.  Full Article

GlycoMimetics qtrly net loss per share $0.34
Monday, 8 May 2017 09:00am EDT 

May 8 (Reuters) - Glycomimetics Inc :Glycomimetics reports program updates and first quarter 2017 results.Qtrly net loss per share $0.34.Glycomimetics inc qtrly loss per share $0.34.Glycomimetics-Phase 3 program to evaluate rivipansel for vaso-occlusive sickle cell crisis, according to pfizer, remains on track for completion in h2 2018.  Full Article

Glycomimetics Q4 loss per share $0.36
Wednesday, 1 Mar 2017 09:30am EST 

Glycomimetics Inc : Glycomimetics reports fourth quarter and year-end 2016 results . Glycomimetics Inc says qtrly loss per share $0.36 . Glycomimetics Inc says as of December 31, 2016, Glycomimetics had cash and cash equivalents of $40.0 million as compared to $46.8 million as of December 31, 2015 .Glycomimetics Inc says qtrly research and development expenses of $6.1 million versus $7.0 million for Q4 of 2015.  Full Article

GlycoMimetics posts Q3 loss of $0.34/share
Friday, 4 Nov 2016 09:15am EDT 

GlycoMimetics Inc: GlycoMimetics reports third quarter 2016 results and progress in clinical development . Qtrly loss per share $0.34 .Revenue for three-month periods ended September 30, 2016 and 2015 was not material.  Full Article

BRIEF-GlycoMimetics says files for mixed shelf of upto $250 mln

* GlycoMimetics Inc says files for mixed shelf of upto $250.0 million - SEC filing‍​ Source text: (http://bit.ly/2xOoKE6) Further company coverage: